Pamela A. Basto

Pamela A. Basto

Auto-generated profile, based on publicly available information

Pamela A. Basto

Summer Medical And Research Training (SMART) student, Baylor College of Medicine, Houston, TX 77030 USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2008 in Nano Letters
Verified
Journal Article
Closed access
RKRohit Karnik
Rohit Karnik
FGFrank Gu
Frank Gu
PBPamela Basto
Pamela Basto
CCChristopher Cannizzaro
Christopher Cannizzaro
LDLindsey Dean
Lindsey Dean
OFOmid C. Farokhzad
Omid C. Farokhzad

22 January 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ASArmon Sharei
Armon Sharei
JZJanet Zoldan
Janet Zoldan
AAAndrea Adamo
Andrea Adamo
WSWoo Young Sim
Woo Young Sim
NCNahyun Cho
Nahyun Cho
KJKlavs F. Jensen
Klavs F. Jensen
Intracellular delivery of macromolecules is a challenge in research and therapeutic applications. Existing vector-based and physical methods have limitations, including their reliance on exogenous materials or electrical fields, which can lead to toxicity or off-target effects. We describe a microfluidic approach to delivery in which cells are mechanically deformed as they pass through a constriction 30–80% smaller than the cell diameter. The resulting controlled application of compression and shear forces results in the formation of transient holes that enable the diffusion of material from the surrounding buffer into the cytosol. The method has demonstrated the ability to deliver a range of material, such as carbon nanotubes, proteins, and siRNA, to 11 cell types, including embryonic stem cells and immune cells. When used for the delivery of transcription factors, the microfluidic devices produced a 10-fold improvement in colony formation relative to electroporation and cell-penetrating peptides. Indeed, its ability to deliver structurally diverse materials and its applicability to difficult-to-transfect primary cells indicate that this method could potentially enable many research and clinical applications.

19 June 2015 in Science
Verified
Journal Article
Closed access
PDF file
GSGeorg Stary
Georg Stary
AOAndrew Olive
Andrew Olive
ARAleksandar F. Radovic-Moreno
Aleksandar F. Radovic-Moreno
DGDavid Gondek
David Gondek
DADavid Alvarez
David Alvarez
UAUlrich H. von Andrian
Ulrich H. von Andrian
The right combination for protection: Despite its prevalence, no vaccine exists to protect against infection with the sexually transmitted bacterium Chlamydia trachomatis . Stary et al. now report on one potential vaccine candidate (see the Perspective by Brunham). Vaccinating with an ultraviolet light-inactivated C. trachomatis linked to adjuvant-containing charged nanoparticles protected female conventional and humanized mice against C. trachomatis infection. The vaccine conferred protection only when delivered through mucosal routes. Protection relied on targeting the bacteria to a particular population of immunogenic dendritic cells and inducing memory T cells that resided in the female genital tract. Science , this issue 10.1126/science.aaa8205 ; see also p. 1322

18 February 2010 in ACS Nano
Verified
Journal Article
Closed access
PVPedro M. Valencia
Pedro M. Valencia
PBPamela A. Basto
Pamela A. Basto
LZLiangfang Zhang
Liangfang Zhang
MRMinsoung Rhee
Minsoung Rhee
RLRobert Langer
Robert Langer
RKRohit Karnik
Rohit Karnik

30 June 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ASArchana Swami
Archana Swami
MRMichaela R. Reagan
Michaela R. Reagan
PBPamela Basto
Pamela Basto
YMYuji Mishima
Yuji Mishima
NKNazila Kamaly
Nazila Kamaly
IGIrene M. Ghobrial
Irene M. Ghobrial
Bone is a favorable microenvironment for tumor growth and a frequent destination for metastatic cancer cells. Targeting cancers within the bone marrow remains a crucial oncologic challenge due to issues of drug availability and microenvironment-induced resistance. Herein, we engineered bone-homing polymeric nanoparticles (NPs) for spatiotemporally controlled delivery of therapeutics to bone, which diminish off-target effects and increase local drug concentrations. The NPs consist of poly(d,l-lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and bisphosphonate (or alendronate, a targeting ligand). The engineered NPs were formulated by blending varying ratios of the synthesized polymers: PLGA-b-PEG and alendronate-conjugated polymer PLGA-b-PEG-Ald, which ensured long circulation and targeting capabilities, respectively. The bone-binding ability of Ald-PEG-PLGA NPs was investigated by hydroxyapatite binding assays and ex vivo imaging of adherence to bone fragments. In vivo biodistribution of fluorescently labeled NPs showed higher retention, accumulation, and bone homing of targeted Ald-PEG-PLGA NPs, compared with nontargeted PEG-PLGA NPs. A library of bortezomib-loaded NPs (bone-targeted Ald-Bort-NPs and nontargeted Bort-NPs) were developed and screened for optimal physiochemical properties, drug loading, and release profiles. Ald-Bort-NPs were tested for efficacy in mouse models of multiple myeloma (MM). Results demonstrated significantly enhanced survival and decreased tumor burden in mice pretreated with Ald-Bort-NPs versus Ald-Empty-NPs (no drug) or the free drug. We also observed that bortezomib, as a pretreatment regimen, modified the bone microenvironment and enhanced bone strength and volume. Our findings suggest that NP-based anticancer therapies with bone-targeting specificity comprise a clinically relevant method of drug delivery that can inhibit tumor progression in MM. Significance Limited treatment options exist for cancer within the bone, as demonstrated by the inevitable, pernicious course of metastatic breast, prostate, and blood cancers. The difficulty of eliminating bone-residing cancer necessitates novel, alternative treatments to manipulate the tumor cells and their microenvironment, with minimal off-target effects. To this end, we engineered bone-homing, stealth nanoparticles to deliver anticancer, bone-stimulatory drugs, and demonstrated their utility with bortezomib (a model drug) and multiple myeloma (a model cancer). To test our hypothesis that increasing bone volume and strength inhibits tumor growth, mice were treated with these nanoparticles before being injected with cancer cells. Results demonstrated significantly slower myeloma growth and prolonged survival. Our research demonstrates the potential of bone-homing nanomedicine as an efficacious cancer treatment mechanism.

31 August 2007 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
LZLiangfang Zhang
Liangfang Zhang
ARAleksandar F. Radovic‐Moreno
Aleksandar F. Radovic‐Moreno
Frank AlexisFrank Alexis
Frank Alexis
FGFrank Gu
Frank Gu
PBPamela A. Basto
Pamela A. Basto
OFOmid C. Farokhzad
Omid C. Farokhzad